Risk factors for venous thromboembolism

Circulation

Volumn 107, Issue SUPPL. 23, 2003, Pages

  Anderson Jr , Frederick A ^a,b   Spencer, Frederick A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Center for Outcomes Research   (United States)

Author keywords

Embolism; Prevention; Risk factors; Thrombus

Indexed keywords

ESTROGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

AGE; BLOOD DISEASE; CANCER; CENTRAL VENOUS CATHETER; COMPRESSION; DISEASE PREDISPOSITION; HEART FAILURE; HIGH RISK PATIENT; HIP FRACTURE; HOSPITALIZATION; HUMAN; IMMOBILIZATION; INTERMITTENT PNEUMATIC COMPRESSION; MAJOR SURGERY; MULTIPLE TRAUMA; PARALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SPINAL CORD INJURY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; LUNG EMBOLISM; PATIENT SELECTION; VEIN THROMBOSIS;

HUMANS; PATIENT SELECTION; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0038042011     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000078469.07362.E6     Document Type: Review

References (111)

1. Anderson, Jr. FA, Wheeler HR. Physicin practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg. 1992;16:707-714.
2. Nicolaides AN, Irving D. Clinical factors and the risk of deep venous thrombosis. In: Nicolaides A, editor. Thromboembalism Etiology. Advances in Prevention and Management. Baltimore, MD: University Park Press; 1975:193-204.
3. Wheeler HB, Anderson FA Jr., Cardullo PA, et al. Suspected deep vein thrombosis. Management by impedance plethysmography. Arch Surg. 1982;117:1206-1209.
4. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245-1248.
5. White RU, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intent Med. 1998;128:737-740.
6. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988;208: 227-240.
7. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988;318: 1162-1173.
8. Gillinov AM, Davis EA, Alberg AJ, et al. Pulmonary embolism in the cardiac surgical patient. Ann Thorac Surg. 1992;53:988-991.
9. Josa M, Siouffi SY, Silverman AB, et al. Pulmonary embolism after cardiac surgery. J Am Coll Cardiol. 1993;21:990-996.
10. Reis SE, Polak JF, Hirsch DR, et al. Frequency of deep venous thrombosis in asymptomatic patients with coronary artery bypass grafts. Am Heart J. 1991;122:478-482.
11. Clarke-Pearson DL, DeLong ER, Synan IS, et al. Variables associated with postoperative deep venous thrombosis: a prospective study of 411 gynecology patients and creation of a prognostic model. Obstet Gynecol. 1987;69:146-150.
12. Gillum RF. Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. Am Heart J. 1987;114:1262-1264.
13. Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Contmoim: 1974;81:311-316.
14. Skillman JJ, Collins RE, Coe NP, et al. Prevention of deep vein thrombosis in urological patients: a controlled, randomized trial of low-dose heparin and external pneumatic compression boots. Surgery. 1978;83:230-234.
15. Frim DM, Barker FG 2nd, Poletti CE, et al. Postoperative low-dose heparin decreases thromboembolic complications in neurosurgical patients. Neurosurgery. 1992;30:830-833.
16. Joffe SN. Incidence of postoperative deep vein thrombosis in neurosurgical patients. J Neurosnrg. 1975;42:201-203.
17. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparn plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 1998;339:80-85.
18. Lindberg F, Rasmussen I, Siegbahn A, et al. Coagulation activation after laparoscopic cholecystectomy in spite of thromboembolism prophylaxis. Surg Endosc. 2000;14:858-861.
19. Bergqvist D, Lowe G. Venous thromboembolism in patients undergoing laparoscopic and arthroscopic surgery and in leg casts. Arch Intern Med. 2002;162:2173-2176.
20. Catheline JM, Turner R, Gaillard JL, et al., Thromboembolism in laparoscrocopic surgery: risk factors and preventive measures. Surg Laparosc Endosc Percutan Tech. 1999;9:135-139.
21. Bergqvist D. Postoperative Thromboembolism. New York: Springer-Verlag, 1983;16-22.
22. Paiement GD, Bell D, Wessinger SJ. New advances in the prevention, diagnosis, and cost effectiveness of venous thromboembolic disease in patients with total hip replacement, in: The Hip, Proceedings of the Fourteenth Open Scientific Meeting of the Hip Society. Saint Louis, C. V. Mosby. 1987;94-119.
23. Stulberg BN, Insall JN, Williams GW, et al. Deep-vein thrombosis following total knee replacement. An analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg Am. 1984;66:194-201.
24. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001:119(Suppl 1):132S-175S.
25. Green D, Lee MY, Lim AC, et al. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med. 1990;113:571-574.
26. Green D, Lee MY, Ito VY, et al. Fixed- vs adjusted-dose heparin in the prophylaxis of thromboembolism in spinal cord injury. JAMA. 1988; 260:1255-1258.
27. Waring WP, Karunas RS. Acute spinal cord injuries and the incidence of clinically occurring thromboembolic disease. Paraplegia. 1991; 29:8-16.
28. Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients: a trial of anticoagulant prophylaxis with phenindione in middle aged and elderly patients with fractured necks or femurs. Lancet. 1959;1959:981-989.
29. Hjelstedt A, Bergvall U. Incidence of thrombosis in patients with tibial fractures. Acta Chir Scand. 1968;134:209-218.
30. Knudson MM, Collins JA, Goodman SB, et al. Thromboembolism following multiple trauma. J Trauma. 1992;32:2-11.
31. O'Malley KF, Ross SE. Pulmonary embolism in major trauma patients. J Trauma. 1990;30:748-750.
32. Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994;331: 1601-1606.
33. Lieberman JS, Borrero J, Urdaneta E, et al. Thrombophlebitis and cancer. JAMA. 1961;177:542-545.
34. Rahr HB, Sorensen JV. Venous thromboembolism and cancer. Blood Coagul Fibrinolysis. 1992;3:451-460.
35. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
36. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344: 1951-1952.
37. Bowcock SJ, Rassani SM, Ward SM, et al. Thromboembolism in patients on thalidomide for myeloma. Hematology. 2002;7:51-53.
38. Clahsen PC, van de Velde CJH, Julien JP, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer/Breast Cancer Cooperative Group Study. J Clin Oncol. 1994; 12:1266-1271.
39. Simmons AV, Sheppard MA, Cox AF. Deep venous thrombosis after myocardial infarction. Lancet. 1973;35:623-625.
40. Samama MM, Cohen AT, Darmon JY, el al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793-800.
41. Kleber FX, Flosbach CW, Koppenhagen K. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in patients with heart failure NYUA III/IV (PRINCE II study). Circulation. 1999;100(Suppl 1):1-619.
42. Geerts W, Cook D, Selby R, et al. Venous thromboembolism and its prevention in critical care. J Crit Care. 2002;17:95-104.
43. Samama MM. Epidemiology of risk factors of deep venous thrombosis (DVT) of the lower limbs in community practice: the SIRIUS study. Thromb Haemost. 1993;69:763.
44. Gjores JE. The incidence of venous thrombosis and its sequelae in certain districts in Sweden. Acta Chir Scand. 1993;111(Suppl 206): 16-24.
45. Emery JL. Pulmonary embolism in children. Arch Dis Child. 1962;37: 591-595.
46. Perlmutt L, Fellows KE. Lower extremity deep vein thrombosis in children. Pediatr Radiol. 1983;13:266-268.
47. Bernstein D, Coupey S, Schonberg SK. Pulmonary embolism in adolescents. Am J Dis Child. 1986;140:667-671.
48. David M, Rivard GE. Thrombosis in pediatric patients. In: JR Leclerc, ed. Venous Thromboembolic Disorders. Philadelphia, PA: Lea & Febiger. 1991:366-381.
49. Kakkar VV, Howe CT, Nicolaides AN, et al. Deep vein thrombosis of the leg. Is there a "high risk" group? Am J Surg. 1970;120:527-530.
50. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intent Med. 2000;160:809-815.
51. Printen KJ, Miller EV, Mason EE, et al. Venous thromboembolism in the morbidly obese. Surg Gynecol Obstet. 1978;147:63-64.
52. Gibbs NM. Venous thrombosis of the lower limbs with particular reference to bedrest. Br J Surg. 1957;45:209-236.
53. Warlow C, Ogston D, Douglas AS. Venous thrombosis following strokes. Lancet. 1972;1:1305-1306.
54. Scurr JH, Machin SJ, Bailey-King S, et al. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial. Lancet. 2001;357:1485-1489.
55. Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. N Engl J Med. 2001;345:779-783.
56. Callus AS, Goghlan DC. Travel and venous thrombosis. Curr Opin Pulm Med. 2002;8:372-378.
57. Thorogood M, Mann J, Murphy M, et al. Risk factors for fatal venous thromboembolism in young women: a case-control study, Int J Epidemiol. 1992;21:48-52.
58. Aaro LA, Juergens JL. Thrombophlebitis associated with pregnancy, Am J Obstet Gynecol. 1971;109:1128-1136.
59. Hogberg U. Maternal deaths in Sweden, 1971-1980. Acta Obstet Gynecol Scand. 1986;65:161-167.
60. Carter C, Gent M. The epidemiology of venous thrombosis, in Hemostasis and Thrombosis. In: RW Coleman, et al., eds. Basic Principles and Clinical Practice. Philadelphia, PA: JB Lippincott Co. 1987: 805-819.
61. Danilenko-Dixon DR,-Heit JA, Silverstein MD, et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol. 2001;184:104-110.
62. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. BMJ. 1969;251-657.
63. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002;65:187-196.
64. Grady D, Applegate W, Bush T, et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials. 1998;19:314-335.
65. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983-987.
66. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348: 977-980.
67. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, et al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol. 1998;147:387-390.
68. Lowe G, Woodward M, Vessey M, et al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost. 2000; 83:530-535.
69. Hoibraaten E, Qvigstad E, Amesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled Estrogen in Venous Thromboembolism Trial (EVTET). Thromb Haemast. 2000;84: 961-967.
70. Lundgren R, Sundin T, Colleen S, et al. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study. Scand J Urol Nephrol. 1986;20:101-105.
71. Petri, M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000;15:145-151.
72. Schved JF, Dupuy-Fons C, Biron C, et al. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study. Haemostasis. 1994;24:175-182.
73. Bick RL. Hypercoagulability and thrombosis. Med Clin North Am. 1994;78:635-665.
74. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117:997-1002.
75. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752-763.
76. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood. 1996;87: 3531-3544.
77. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516. Abstract.
78. Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370-1373.
79. Comp P, Esmon C. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med. 1984;311:1525-1528.
80. Dahlback B, Carlsson M, Svertsson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004-1008.
81. Poort SR, Rosendaal FR, Reitsma, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
82. Heijboer H, Brandjes DP, Buller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512-1516.
83. Tabemero MD, Tomas JF, Alberca I, et al. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol. 1991;36:249-254.
84. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol. 1981;10:369-390.
85. Allaart CF, Poort SR, Rosendaal FR, et al. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet. 1993;341:134-138.
86. Pabinger I, Brucker S, Kyrle PA, et al. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis. 1992;3:547-553.
87. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-1506.
88. Svensson PJ, Dahlback, B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
89. Ridker PM, Glynn RJ, Milctich JP, et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997;126:528-531.
90. Vandenbroucke JP, Koster T, Briët E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-1457.
91. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999; 341:801-806.
92. Koster T, Blann AD, Briët E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152-155.
93. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83:5-9.
94. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457-462.
95. van Hylckama Vlieg A, van der Linden IK, Bertina RM, et al. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95:3678-3682.
96. Meijers JCM, Tekelenburg WLH, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342:696-701.
97. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
98. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998;80: 874-877.
99. Baker LW, Prajapat DK. Deep vein thrombosis in African and Indian patients. S Afr J Surg. 1974;12:127-131.
100. Cunningham IG, Yong, NK. The incidence of postoperative deep vein thrombosis in Malaysia. Br J Surg. 1974;61:482-483.
101. Kniffin, WD Jr., Baron JA, Barren J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994;154:861-866.
102. Anderson FA Jr., Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med, 1991;151:933-938.
103. Prevention of venous thromboembolism in surgical patients by low-dose heparin: prepared by the Council on Thrombosis of the Am Heart Association. Circulation. 1977;55:423A-426A.
104. Goldhaber SZ, Morpurgo M. Diagnosis, treatment, and prevention of pulmonary embolism. Report of the WHO/International Society and Federation of Cardiology Task Force. JAMA. 1992;268:1727-1733.
105. Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA. 1986;256:744-749.
106. Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. Ann Intern Med. 1980;93:141-144.
107. Huber O, Bounameaux H, Borst F, et al. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg. 1992;127:310-313.
108. Scurr JH. How long after surgery does the risk of thromboembolism persist? Acta Chir Scand Suppl. 1990;556:22-24.
109. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335:696-700.
110. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996;348:224-228.
111. Bergqvist D, Agnelli G, Cohen AT, et al., Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975-980.